2025-04-09 - Analysis Report
## Teva Pharmaceutical Industries Ltd ADR (TEVA) Stock Review

**0. Key Figures & Initial Analysis:**

TEVA's cumulative return significantly lags behind the S&P 500 (VOO).  While TEVA showed a 31.31% return, VOO achieved 56.32%, resulting in a considerable gap.  The relative divergence indicator suggests TEVA's performance is significantly below the VOO's historical performance range.

**1. Performance Comparison & Alpha/Beta Analysis:**

Teva Pharmaceutical Industries Ltd ADR is a generic pharmaceutical company.  The provided data shows TEVA's substantial underperformance compared to the S&P 500 (VOO) with a cumulative return difference of -25.0 percentage points.  This is illustrated by the negative alpha values consistently shown across all periods in the provided table.  The beta values fluctuate, but generally show a high sensitivity to market movements, exceeding 1 in several periods.  The market capitalization (Cap(B)) shows some variability. The substantial negative alpha across multiple years indicates that TEVA has underperformed the market consistently.


| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | -44.0% | 58.4% | -73.0% | -0.0 | 21.8 |
| 2016-2018  | -41.0% | 70.4% | -59.0% | -0.1 | 17.7 |
| 2017-2019  | -16.0% | 70.4% | -45.0% | -0.2 | 11.2 |
| 2018-2020  | 0.0% | 70.4% | -25.0% | -0.2 | 11.1 |
| 2019-2021  | -22.0% | 58.3% | -76.0% | -0.2 | 9.2 |
| 2020-2022  | 27.0% | 74.8% | 20.0% | -0.2 | 10.5 |
| 2021-2023  | 38.0% | 74.8% | 21.0% | -0.8 | 12.0 |
| 2022-2024  | 122.0% | 74.8% | 106.0% | -0.7 | 25.3 |
| 2023-2025  | 41.0% | 76.0% | 37.0% | -0.2 | 15.6 |


**2. Recent Price Movement:**

* **Closing Price:** $13.63
* **Last Market Change:** -$0.305 (-2.19%) - indicating a recent price drop.
* **5-Day Moving Average:** $14.57
* **20-Day Moving Average:** $15.68
* **60-Day Moving Average:** $17.30

The price is below all three moving averages, suggesting a downtrend.


**3. Technical Indicators & Expected Return:**

* **Market Risk Indicator (MRI):** 0.4883 (High Risk) – indicating a high level of market risk.
* **RSI:** 10.31 (Extremely oversold) – suggesting the stock is significantly undervalued.
* **PPO:** -1.08 (Bearish) – confirming the downtrend.
* **20-Day Relative Divergence Change:** -0.1 (Short-term decline) – reinforces the negative trend.
* **Expected Return:** -36.5% – a significantly negative expected return.
* **Long-term (2+ years) S&P 500 vs TEVA:**  Given the negative alpha and current market sentiment,  a significant underperformance against the S&P 500 is projected over the long term.


**4. Recent Earnings Analysis:**

| Date       | EPS    | Revenue      |
|------------|--------|--------------|
| 2024-11-06 | -$0.39 | $4.33 B      |
| 2024-07-31 | -$0.75 | $4.16 B      |
| 2024-05-08 | -$0.12 | $3.82 B      |
| 2023-11-09 | $0.07  | $3.85 B      |
| 2024-02-12 | $0.06  | $3.85 B      |

Recent earnings show significant volatility and negative EPS in several quarters. While revenue remains relatively stable, the consistent negative EPS is a major concern.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2024-12-31 | $4.23B | 50.15% |
| 2024-09-30 | $4.33B | 49.60% |
| 2024-06-30 | $4.16B | 48.61% |
| 2024-03-31 | $3.82B | 46.37% |
| 2023-12-31 | $4.46B | 54.18% |

Profit margins are relatively high but show a declining trend.  Revenue is somewhat consistent but exhibits some fluctuations.

**Capital and Profitability:**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2024-12-31 | $5.37B | -4.04% |
| 2024-09-30 | $6.07B | -7.21% |
| 2024-06-30 | $6.36B | -13.30% |
| 2024-03-31 | $7.28B | -1.91% |
| 2023-12-31 | $7.51B | 5.72% |

Negative ROE across several quarters indicates that the company is not generating sufficient returns on its equity.  This is a significant red flag.


**6. Overall Analysis:**

TEVA's performance is deeply concerning.  The stock significantly underperforms the S&P 500, shows negative alpha consistently, and displays negative ROE and declining profit margins. While the RSI suggests the stock might be oversold, the negative earnings, high risk indicators (MRI), and overall negative trend strongly advise against investment unless a significant turnaround in the company's fundamentals is observed. The recent price drop further exacerbates the negative outlook.  A long-term investment strategy requires careful consideration and a thorough understanding of the underlying risks.  Further due diligence is crucial before considering any investment in TEVA.
